Phibro Animal Health (NASDAQ:PAHC) Stock Rating Upgraded by StockNews.com

Phibro Animal Health (NASDAQ:PAHC) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Tuesday.

Other equities research analysts have also recently issued reports about the stock. Barclays boosted their price target on shares of Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a research report on Tuesday. Bank of America boosted their price target on shares of Phibro Animal Health from $13.00 to $15.00 and gave the stock an “underperform” rating in a research report on Friday, August 30th. Finally, JPMorgan Chase & Co. started coverage on shares of Phibro Animal Health in a research report on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 price target on the stock. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Phibro Animal Health presently has a consensus rating of “Hold” and an average target price of $16.50.

Phibro Animal Health Price Performance

Shares of NASDAQ PAHC opened at $25.27 on Tuesday. Phibro Animal Health has a fifty-two week low of $9.49 and a fifty-two week high of $25.98. The firm’s 50-day simple moving average is $22.57 and its 200 day simple moving average is $19.61. The company has a quick ratio of 1.69, a current ratio of 3.23 and a debt-to-equity ratio of 1.81. The stock has a market cap of $1.02 billion, a P/E ratio of 58.77, a P/E/G ratio of 0.66 and a beta of 0.51.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings results on Wednesday, August 28th. The company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.34 by $0.07. Phibro Animal Health had a net margin of 1.67% and a return on equity of 21.59%. The firm had revenue of $273.16 million for the quarter, compared to analysts’ expectations of $262.44 million. Equities analysts expect that Phibro Animal Health will post 1.59 EPS for the current year.

Insider Transactions at Phibro Animal Health

In related news, Director E Thomas Corcoran purchased 5,000 shares of Phibro Animal Health stock in a transaction dated Wednesday, September 4th. The stock was acquired at an average cost of $20.02 per share, with a total value of $100,100.00. Following the completion of the transaction, the director now directly owns 25,000 shares of the company’s stock, valued at $500,500. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 50.07% of the stock is owned by insiders.

Institutional Trading of Phibro Animal Health

A number of hedge funds have recently made changes to their positions in the stock. Brandes Investment Partners LP lifted its position in shares of Phibro Animal Health by 1.2% in the second quarter. Brandes Investment Partners LP now owns 2,405,629 shares of the company’s stock worth $40,521,000 after purchasing an additional 29,071 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Phibro Animal Health by 5.7% during the second quarter. Dimensional Fund Advisors LP now owns 775,470 shares of the company’s stock valued at $13,005,000 after acquiring an additional 42,086 shares in the last quarter. Acadian Asset Management LLC raised its position in Phibro Animal Health by 6.3% during the second quarter. Acadian Asset Management LLC now owns 717,506 shares of the company’s stock valued at $12,027,000 after acquiring an additional 42,299 shares in the last quarter. Dana Investment Advisors Inc. raised its position in Phibro Animal Health by 17.2% during the second quarter. Dana Investment Advisors Inc. now owns 513,926 shares of the company’s stock valued at $8,619,000 after acquiring an additional 75,546 shares in the last quarter. Finally, American Century Companies Inc. raised its position in Phibro Animal Health by 119.6% during the second quarter. American Century Companies Inc. now owns 347,191 shares of the company’s stock valued at $5,822,000 after acquiring an additional 189,068 shares in the last quarter. 99.34% of the stock is owned by hedge funds and other institutional investors.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.